Latest Breaking News On - Apellis pharmaceuticals stock performance - Page 1 : comparemela.com

Apellis Pharmaceuticals (NASDAQ:APLS) Stock Rating Reaffirmed by HC Wainwright

Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $92.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 123.79% from the company’s previous close. […]

Pascal deschateletsRobertw bairdTimothy eugene sullivanPolar capital holdings plcApellis pharmaceuticals incApellis pharmaceuticals stock performanceNorges bankVanguard group incJefferies financial groupNews ratings for apellis pharmaceuticals dailyApellis pharmaceuticalsJpmorgan chase coSecurities exchange commissionWells fargo companyAnalyst recommendations for apellis pharmaceuticalsPricet rowe associates inc

Wells Fargo & Company Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $48 00

Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its target price trimmed by Wells Fargo & Company from $57.00 to $48.00 in a research report sent to investors on Thursday morning, Benzinga reports. The firm currently has an equal weight rating on the stock. Other equities analysts have also recently issued research reports about the stock. […]

Robertw bairdPascal deschateletsCedric francoisNeedham companyCovestor ltdWells fargo companyApellis pharmaceuticals stock performanceSecurities exchange commissionFinancial wealth managmentApellis pharmaceuticalsWoodward diversified capitalAnalyst recommendations for apellis pharmaceuticalsNews ratings for apellis pharmaceuticals dailyApellis pharmaceuticals incJpmorgan chase coHedge funds weigh in on apellis pharmaceuticals

Apellis Pharmaceuticals (NASDAQ:APLS) Earns Buy Rating from Needham & Company LLC

Apellis Pharmaceuticals (NASDAQ:APLS) Earns Buy Rating from Needham & Company LLC
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Raymond jamesZurcher kantonalbank zurich cantonalbankNur nicholsonAdamj townsendApellis pharmaceuticals incFirst horizon advisors incApellis pharmaceuticals company profileApellis pharmaceuticals stock performanceAnalyst recommendations for apellis pharmaceuticalsGoldman sachs groupApellis pharmaceuticalsAssetmark incJpmorgan chase coNeedham companyYork mellon corpSecurities exchange commission

Apellis Pharmaceuticals (NASDAQ:APLS) Issues Earnings Results, Meets Expectations

Apellis Pharmaceuticals (NASDAQ:APLS) Issues Earnings Results, Meets Expectations
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

A sinclair dunlopRobertw bairdAdamj townsendApellis pharmaceuticalsApellis pharmaceuticals stock performanceApellis pharmaceuticals incSecurities exchange commissionInsider activity at apellis pharmaceuticalsJpmorgan chase coNews ratings for apellis pharmaceuticals dailyGoldman sachs groupEarnings history for apellis pharmaceuticalsGet free reportExchange commissionApellis pharmaceuticals daily

Apellis Pharmaceuticals (NASDAQ:APLS) Announces Quarterly Earnings Results, Hits Estimates

Apellis Pharmaceuticals (NASDAQ:APLS) Announces Quarterly Earnings Results, Hits Estimates
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

Timothy eugene sullivanRaymond jamesDavido watsonApellis pharmaceuticals stock performanceApellis pharmaceuticalsApellis pharmaceuticals incNews ratings for apellis pharmaceuticals dailyEarnings history for apellis pharmaceuticalsGoldman sachs groupInsider transactions at apellis pharmaceuticalsSecurities exchange commissionGet free reportEugene sullivanExchange commissionGeneral counsel davidApellis pharmaceuticals daily